Background: Cervical cancer being the cancer of cervix is caused by an aberrant cell
growth that acquires an ability to spread/ invade to other body parts. It has also been reported to be the
second most common cause of death and cancer among women. Based on the severity of the disease,
treatment aspects need to be explored more in order to overcome the limitations acquired by the conventional
treatment. Recently, nanocarriers based drug delivery systems including liposomes, nanofibres,
metallic NPs, polymeric NPs, dendrimers, polymeric micelles, antibody-drug conjugates, etc.
have been explored to target and treat cervical cancer.
Objective: This review highlights numerous recent research and patent reports as well on nanocarriers
Methods: Patents viz US, EP and WIPO have been retrieved using sites www.uspto.gov/patft and
www.freepatentsonline.com to collect literature on nanocarriers.
Results: Various research reports and patents revealed nanocarriers to be effective in treating cervical
cancer and these carriers are observed to be safer than the conventional treatment.
Conclusion: Nanocarriers result in transforming drug distribution that can overpower drug resistance.
Further, nanocarriers based drug delivery systems can particularly target drugs to cellular, subcellular
and tissue sites. By enhancing the drug’s bioavailability at the desired site, these systems result in
therapeutic benefits like enhanced safety and efficacy. Also, in combination with other treatment approaches
like radiation, photothermal and gene therapy, nanocarriers are reported to be quite effective
and can define novel strategies to combat cervical cancer.